Abstract
New methods that have been developed to regulate and modify the biological response of tumors and of normal tissues to radiation to achieve maximum benefit with minimum harm to the adjacent normal tissues should be considered be among the most significant developments in radiotherapy (RT) in recent years. These methods include different fractionation schemes, the application of chemical and biological agents, and effective therapies targeted toward molecular pathway-signal transduction mechanisms. Among these treatment strategies, the most widely used method in clinical practice is the combination of chemotherapy (CT) with RT. Since the development of CT and RT, many studies have been published regarding adjuvant treatment of breast cancer, which remains a controversial issue. However, despite advances and innovations in breast cancer treatment, there is still no consensus on the optimal treatment approach, mainly because breast cancer is a heterogeneous group of diseases with a wide spectrum of biological behaviors. In this section, the molecular biological mechanisms of the interaction between RT and CT in breast cancer, as well as the optimal timing of RT and CT, will be discussed in light of relevant randomized trials.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys. 1979;5:85–91.
Choy H, MacRae R, Story M. Basic concepts of chemotherapy and irradiation interaction. In: Halperin EC, Perez CA, Brady LW, editors. Principles and practice of radiation oncology. 5th ed. Philadelphia, USA: Lippincott Williams & Wilkins; 2008. p. 669–88.
Gregoire V, Baumann M. Combined radiotehapy and chemotherapy. In: Joiner M, van der Kogel A, editors. Basic clinical radiobiology. 4th ed. London: Edward Arnold; 2009. p. 246–58.
MacRae RM, Choy H. Taxanes in combined modality therapy. In: Choy H, editor. Chemoradiation in cancer therapy. 1st ed. New Jersey: Humana Press Totowa; 2003. p. 65–92.
Milas L, Fujii T, Hunter N, et al. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res. 1999;59:107–14.
Kumar P. Tumor hypoxia and anemia: impact on the efficacy of radiation therapy. Semin Hematol. 2000;37:4–8.
Milas L, Hunter N, Mason KA, Milross C, Peters LJ. Tumor reoxygenation as a mechanism of taxol-induced enhancement of tumor radioresponse. Acta Oncol. 1995;34:409–12.
Bellon JR. A prospective study of concurrent cyclophosphamide/methotrexate/5-fluorouracil and reduced-dose radiotherapy in patients with early-stage breast carcinoma. Cancer. 2004;7:1358–64.
Arcangeli G, Pinnaro P, Rambone R, et al. A phase III randomized study on the sequencing of radiotherapy and chemotherapy in the conservative management of early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2006;64:161–7.
Toledano A, Azria D, Garaud P, et al. Phase III Trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for Early Stage Breast Cancer: final results of the ARCOSEIN Trial. J Clin Oncol. 2007;25:405–10.
Toledano A, Garaud P, Serin D, et al. Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conservative surgery enhances late toxicities. Cancer Radiother. 2006;10:158–67.
Wallgren A, Bernier J, Gelber RD, et al. Timing of radiotherapy and chemotherapy following breast-conserving surgery for patients with node-positive breast cancer. International Breast Cancer Study Group. Int J Radiat Oncol Biol Phys. 1996;35:649–59.
Bull JM, Torney DC, Li SH, et al. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer. 1978;41:1649–57.
Clark RM, Wilkinson RH, Miceli PN, MacDonald WD. Breast cancer: experiences with conservation therapy. Am J Clin Oncol. 1987;10:461–8.
Early Breast Cancer Trialists’ Collaborative Group. Effects of radiotherapy and surgery in early breast cancer: an overview of the randomized trials. N Engl J Med. 1995;333:1444–55.
Shapiro CL, Hardenbergh PH, Gelma R, et al. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol. 1998;16:3493–501.
Fiets WE, van Helvoirt RP, Nortier JW, et al. Acute toxicity of concurrent adjuvant radiotherapy and chemotherapy (CMF or AC) in breast cancer patients. A prospective, comparative, non-randomised study. Eur J Cancer. 2003;39:1081–8.
Recht A, Come SE, Henderson IC, et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med. 1996;33:1356–61.
Bellon JR, Come SE, Gelman RS, et al. Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial. J Clin Oncol. 2005;23:1934–40.
Cakır S, Gursel B, Meydan D, Yıldız L. The sequencing of radiation therapy and chemotherapy after mastectomy in premenopausal women with breast cancer. Jpn J Clin Oncol. 2003;33:563–9.
Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tummors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol. 1990;8:1483–96.
Hickey BE, Francis D, Lehman MH. Sequencing of chemotherapy and radiation therapy for early breast cancer. Cochrane Database Syst Rev. 2006;4:CD005212.
Wahl AF, Donaldson KL, Fairchild C, et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med. 1996;2:72–9.
Vikhanskaya F, Vignati S, Beccaglia P, et al. Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis. Exp Cell Res. 1998;241:96–101.
Zaffaroni N, Silvestrini R, Orlandi L, et al. Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and -resistant human ovarian cells. Br J Cancer. 1998;77:1378–85.
Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21:976–83.
De Laurentiis M, Cancello G, D’Agostino D, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol. 2008;26:44–53.
Skinner KA, Silberman H, Florentine B, et al. Preoperative paclitaxel and radiotherapy for locally advanced breast cancer: surgical aspects. Ann Surg Oncol. 2000;7:145–9.
Bellon JR, Lindsley KL, Ellis GK, et al. Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer. Int J Radiat Oncol Biol Phys. 2000;48:393–7.
Ellerbroek N, Martino S, Mautner B, et al. Breast-conserving therapy with adjuvant paclitaxel and radiation therapy: feasibility of concurrent treatment. Breast J. 2003;9:74–8.
Hanna YM, Baglan KL, Stromberg JS, et al. Acute and subacute toxicity associated with concurrent adjuvant radiation therapy and paclitaxel in primary breast cancer therapy. Breast J. 2002;8:149–53.
Formenti SC, Volm M, Skinner KA, et al. Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and post-operative doxorubicin based chemotherapy in locally advanced breast cancer: a phase I/II tiral. J Clin Oncol. 2003;21:864–70.
Taghian AG, Assaad S, Niemierko A, et al. Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel. J Natl Cancer Inst. 2001;93:1806–11.
Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005;23:3686–96.
Francis P, Crown J, Di Leo A, et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02–98 randomized trial. J Natl Cancer Inst. 2008;100:121–33.
Bellon JR, Harris JR. Chemotherapy and radiation therapy for breast cancer: what is the optimal sequence? J Clin Oncol. 2005;23:5–7.
Sartor CI, Peterson BL, Woolf S, et al. Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node positive breast cancer: Cancer and Leukemia Group B 9344. J Clin Oncol. 2005;23:30–40.
Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer. Ann Oncol. 2005;16:1569–83.
Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736–47.
National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2012. Breast Cancer. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
Fisher ER, Wang J, Bryant J, et al. Pathobiology of preoperative chemotherapy: findings from National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer. 2002;95:681–95.
van der Hage JA, Cornelis JH, van de Velde CJ, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001;19:4224–37.
Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26:778–85.
Huang EH, Tucker SL, Strom EA, et al. Radiation treatment improves local-regional control and cause-specific survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol. 2004;22:4691–9.
Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996;14:2738–46.
Recht A. Breast cancer. In: Gunderson LL, Tepper JE, editors. Clinical radiation oncology. 2nd ed. New York: Elsevier Churchill Livingstone; 2007. p. 1475–502.
Morrow M. Breast conservation and negative margins: how much is enough? Breast. 2009;18:S84–6.
Recht A, Come SE, Gelman RS, et al. Integration of conservative surgery, radiotherapy, and chemotherapy for the treatment of early-stage node positive breast cancer: sequencing, timing, and outcome. J Clin Oncol. 1991;9:1662–7.
Haffty MD, Vicini FA, Beitsch P, et al. Timing of chemotherapy after mammosite radiation therapy system breast brachytherapy: analysis of the American Society of breast surgeons mammosite breast brachytherapy registry trial. Int J Radiat Oncol Biol Phys. 2008;72:1441–8.
Vaidya JS, Baum M, Tobias JS, et al. Long-term results of targeted introoperative radiotherapy (TARGIT) boost during breast-conserving surgery. Int J Radiat Oncol Biol Phys. 2011;81:1091–7.
Halsted WS. The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June 1889 to January 1894. Ann Surg. 1894;20:497–555.
Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis. JAMA. 2011;305:569–75.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Gursel, B., Haydaroglu, A. (2013). Interaction of Chemotherapy, Radiotherapy, and Timing. In: Haydaroglu, A., Ozyigit, G. (eds) Principles and Practice of Modern Radiotherapy Techniques in Breast Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5116-7_6
Download citation
DOI: https://doi.org/10.1007/978-1-4614-5116-7_6
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-5115-0
Online ISBN: 978-1-4614-5116-7
eBook Packages: MedicineMedicine (R0)